Please assess the completion status of the following clinical trial:

Trial Title: Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6 weeks through exactly 12 weeks~* Healthy infants~Exclusion Criteria:~* Clinical evidence of active gastrointestinal illness~* Fever, with a rectal temperature of greater than and equal to thirty eight degree celsius at the time of immunization~* History of congenital abdominal disorders, intussusception, or abdominal surgery~* History of known prior rotavirus disease~* Known or suspected impairment of immunological function~* Prior administration of any rotavirus vaccine~* Known hypersensitivity to any component of the rotavirus vaccine, e.g. trypsin

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- RotaTeq™ Vaccine (V260) (Type: EXPERIMENTAL): Evaluation of Safety, Tolerability and Immunogenicity of Vaccination with RotaTeq™ in Healthy Infants in India.

Based on this trial design, predict the completion outcome and termination type (if applicable).